Posted by Michael Wonder on 11 Nov 2023
Bayer’s aflibercept 8 mg recommended for approval in EU
10 November 2023 - Recommendation by the CHMP based on positive results from PULSAR clinical trial in neovascular (wet) age-related macular degeneration and PHOTON trial in diabetic macular oedema.
The CHMP of the EMA has adopted a positive opinion recommending aflibercept 8 mg with extended treatment intervals in two major retinal eye diseases, neovascular (wet) age-related macular degeneration and diabetic macular oedema for approval.
